Introduction
Multiple myeloma (MM) is a disease of the elderly with more than one-half of the patients over 65 years of age at diagnosis. 1 While various studies have suggested that age at diagnosis is an adverse prognostic factor, it is likely that multiple factors contribute to this finding. [1] [2] [3] These include the presence of other co-morbidities which in addition to decreasing survival may also limit therapeutic options, lack of inclusion of older patients in clinical trials evaluating newer therapies, poorer performance status, 1 referral bias as well as less use of aggressive approaches such as highdose chemotherapy (HDT). Studies suggest that older patients treated in a similar fashion derive the same benefit as their younger counterparts. 4 However, these retrospective studies clearly have selection bias with inclusion of older patients with better performance status and, therefore, may not be widely applied. HDT is an accepted and effective therapy for myeloma and remains the standard of care for those eligible to undergo the procedure. [5] [6] [7] With improvements in supportive care resulting in increased safety of HDT, it is increasingly being offered to older patients, as suggested by data from the blood and marrow transplant registry. 8 Nearly one-fifth of the autologous transplants reported to the registry in 2004-2005 were for patients over 65 years compared to 5% from a decade earlier. While prospective trials have not included this population (over 65 years of age), current evidence suggests that HDT is efficacious and tolerable in the elderly patient with myeloma. [9] [10] [11] [12] [13] [14] [15] The concept of dose intensity and role of high-dose melphalan for the treatment of MM was initially introduced by McElwain and Powles 16 in the early 1980s. While impressive response rates were seen, it was accompanied by a high treatment-related mortality secondary to prolonged bone marrow suppression. The next major milestone was the introduction of stem cell rescue in combination with high-dose melphalan. Barlogie et al. 17 used a regimen of high-dose melphalan and total-body irradiation combined with autologous bone marrow transplantation in patients refractory to therapy with vincristine -adriamycindexamethasone (VAD). This approach, while allowing rapid and profound reduction in the tumor burden, allowed rapid reconstitution of normal hematopoiesis and resulted in reduced mortality. Since these initial studies, several critical questions regarding the HDT have been addressed through well-designed phase III randomized clinical trials.
HDT improves survival compared to conventional therapy in patients with myeloma
HDT has been demonstrated to confer a survival advantage for patients with myeloma in several randomized clinical trials. The Intergroupe Franc¸ais du Mye´lome (IFM) randomized 200 previously untreated patients, under the age of 65 years, to receive either conventional chemotherapy or HDT. 5, 18 HDT resulted in a superior response rate (81% including 22% complete remission (CR) and 1% very good partial remission (VGPR)) compared to the conventional therapy arm (57% with 5% CR and 9% VGPR), which translated into a better event free (5-year EFS of 28% in the HDT group and 10% in the conventional-dose group) as well as OS (5-year OS of 52% in the HDT group and 12% in the conventional-dose group). The Medical Research Council Myeloma VII Trial randomized 407 patients with previously untreated MM, less than 65 years of age again, to either standard conventional-dose combination chemotherapy or HDT. Similar to the IFM trial, HDT resulted in higher CR rates compared to standard therapy (44 vs 8%) and similar partial response rates (42 and 40%, respectively; P ¼ 0.72). Patients receiving HDT had a superior OS (median survival of 54.1 vs 42.3 months) and progression-free survival (PFS) (31.6 vs 19.6 months). The Groupe Mye´lome Autogreffe conducted a prospective randomized trial (MAG91) that assigned 191 patients with previously untreated MM, aged 55-65 years, to receive either conventional chemotherapy or HDT. 7 The trial confirmed the improved EFS with HDT (25 vs 19 months), but failed to demonstrate any improvement in the OS (47.8 months for HDT vs 47.6 months in the conventional chemotherapy (CCT) group). The period of time without symptoms, treatment and treatment toxicity (TWiSTT) was significantly longer for the HDT patients than for the conventional therapy group. The lack of a survival advantage may have been due to not all patients in the HDT arm receiving a transplant and nearly one-fifth of the patients in the conventional therapy arm receiving HDT as salvage therapy. The intergroup study S9321 randomized patients with untreated myeloma to either HDT or standard therapy followed by further randomization of responding patients between interferon (IFN) maintenance and no maintenance treatment. 19 At a median follow-up of 76 months, there were no differences in response rates, PFS or OS between the groups.
What is the role of HDT in patients over 65 years?
The clinical trials addressing the utility of HDT in MM have for the most part included patients younger than 65 years, who represent less than half of the newly diagnosed patient population. Significant numbers of patients over age 65 years do undergo HDT; among 678 consecutive patients who underwent HDT at our institution, 137 (20%) were over 65 years. 20 However, considering that nearly 64% of patients with a new diagnosis of myeloma are 65 years or older (surveillance epidemiology and end results (SEER) Data), it translates to a small proportion of patients over age 65 years who go on to HDT. It, nevertheless, remains an important question given the aging of the population, and the increasing number of individuals where the question of HDT has to be addressed. The improved health of the population and the increased life expectancy will bring about additional challenges for the physicians faced with the question regarding the role and feasibility of HDT. These patients will continue to have a better performance status, and physicians will need to estimate the treatment benefits of an intensive approach in view of improved average life expectancies.
There remain several challenges to aggressive treatment approaches in older patients. With increasing life expectancy, many of the older patients will have other comorbidities. While many of these co-morbidities are likely to be well controlled, the impact of intense therapies on them will have to be carefully considered before deciding on HDT. In a retrospective analysis of 500 consecutive patients with various hematological malignancies who underwent autologous hematopoietic-cell transplant, the EFS was inferior for patients over 50 years and this group also had higher regimen-related mortality rates. 21 Higher treatment-related mortality was also observed in another study comparing ASCT for various hematological malignancies for those over 50 years, but with no differences in the EFS. 22 Several retrospective studies have examined the role of HDT in patients over age 65 years and have come to the conclusion that it benefits a select group of the older patients with good performance status. [9] [10] [11] 13, 14, 20, [23] [24] [25] Among the 678 consecutive patients transplanted at Mayo Clinic between 1989 and 2005, 20% of patients were over 65 years. 20 We did not find any difference in terms of the response rates, treatment-related mortality, OS or PFS following HDT in the older group compared to those 65 years or younger. The melphalan dose was reduced to 140 mg/m 2 for 15% of patients over 65 years and reduced for only 5% of patients 65 years or younger. However, there was a trend toward longer hospitalization and higher incidence of bacteremia among the older patients. We have reviewed our experience with high-dose therapy for patients (n ¼ 35) over 70 years (median 72 years; range 70-76 years) comparing the outcome to 70 matched patients (median age 55 years; range 37-65 years) (two matches for each patient). 9 Matching was based on stage at transplant (primary refractory, plateau phase, relapse off therapy or relapse on therapy), Durie Salmon stage, high or low labeling index, conventional cytogenetics (abnormal vs normal), presence or absence of circulating plasma cells at time of transplant and whether cyclophosphamide was used as part of mobilization. Ten of the older patients received reduced dose melphalan (140 mg/m 2 ) compared to three patients in the control group. The overall response rate was similar for the two groups (97% for the older patients compared to 96% for the control group) with 11 (31%) of the older patients and 17 (24%) of the control patients achieving a CR. The post transplant PFS estimate at 1-year post transplant was 65% for the older patients compared to 66% for the control group (P ¼ 0.3). The 2-year estimated OS from transplant was similar in the two groups; 58% for the older patients compared to 67% for the control group. The OS from diagnosis was also similar for the two groups. The treatment-related toxicity and mortality were comparable between the two groups.
Siegel et al. 10 identified 49 patients over age 65 years from among 550 patients with MM undergoing HDT (median age 67 years; range 65-76 years) and compared their outcome to that of a matched set of 49 younger patients (median 52 years; range 37-64 years). Patients were matched for cytogenetics, b2-microglobulin, C-reactive protein, albumin and creatinine, and all received high-dose melphalan-based therapy with 76% of the younger and 65% of the older group completing a second transplant. Stem cell collection, engraftment kinetics and toxicities were similar between the two groups. Treatment-related mortality was 2% in younger and 8% among older subjects and the EFS and OS were similar for both groups. In this group of patients, pre-transplant cytogenetics and b2-microglobulin were prognostic for both EFS and OS, and age had no impact. Badros et al.
11 examined their experience with 70 patients over 70 years (median 72 years; range 70-83 years), of whom 34 had newly diagnosed myeloma. Excessive mortality (16%) was noted among the initial 25 patients and hence the remaining patients received only 140 mg/m 2 of melphalan. The engraftment kinetics was comparable to those expected with a CR rate of 20%, which improved to 27% for the 31 patients (44%) who went on to a tandem auto-SCT. Median CR duration was 1.5 years and was significantly longer for patients with less than a year of therapy before HDT (2.6 vs 1.0 years) and the 3-year EFS and OS were projected at 20 and 31%, respectively. A benefit was seen with tandem transplants in this group of patients with respect to OS (4.0 vs 1.4 years) and EFS (4.0 vs 0.7 years).
Reece et al. 12 examined the data reported to the Autologous Blood and Marrow Transplant Registry and compared the outcome of 110 patients X60 years (median 63 years; range 60-73 years) with that of 382 patients under 60 years (median 52 years; range 30-59 years). Treatmentrelated mortality at 100 days and at 1 year was similar for the two groups. The relapse rate, PFS and OS in the two groups were also similar. In another study, 22 myeloma patients over 65 years were compared to 79 patients treated on identical HDT protocols. 13 The stem cell collection yields, engraftment and other mortality were similar for the two groups. Elderly patients tended to have more mucositis and gastrointestinal toxicity when compared to the younger patients in this study. There was no difference between the two groups in terms of the response rates or OS and relapse-free survival. 13 Similar results were arrived at in another small study. 14 Other studies have suggested a shorter PFS in elderly patients. 26 Italian investigators studied the role of intermediate-dose melphalan in older patients. Seventy-one patients (median age 64 years) treated with two or three courses of melphalan 100 mg/m 2 (MEL100) followed by stem cell support were compared to the other 71 patients (matched for age and b2-microglobulin) who were treated with oral melphalan and prednisone (MP). 23 CR was 47% after MEL100 and 5% after MP with a median EFS of 34 and 17.7 months, respectively. Median OS was over 56 months for MEL100 and 48 months for MP. This was followed by a randomized trial which enrolled 194 newly diagnosed patients receiving either conventional chemotherapy (six courses of oral MP) or intermediate-dose therapy (two courses of melphalan at 100 mg/m 2 ) with stem cell support. 27 MEL100 resulted in higher overall responses including near-complete remission (nCR) (25 vs 6%). At 3 years, MEL100 arm had an EFS of 37% compared to 16%, and OS of 77% compared to 62% for the MP arm. When patients aged 65-70 years were analyzed separately, the results were similar. Among this group, the median OS was 58 months with MEL100 compared to 37.2 months for the MP arm.
However, the recently presented results of the IFM 99-06 trial did not confirm the survival advantage seen among the elderly patients with intermediate-dose melphalan in this trial, even though the response rates were higher than with MP. 28 The IFM 99-06 randomized patients aged 65-75 years to MP (12 courses at 6-week intervals), MP-THAL (MP plus thalidomide (THAL) at the maximum tolerated dose up to 400 mg/day, stopped at the end of MP) or MEL100 and stem cell transplant following two cycles of VAD. The MEL100 arm had equivalent EFS (19 vs 17.1 months) and OS (38.6 vs 30.3 months) compared to the MP arm. This at least partially reflects the differences in the duration of conventional therapy in the two trials, 6 months in the Italian study compared to the 12 months in the French study.
While most of the randomized trials evaluating HDT have examined its role in patients with newly diagnosed myeloma, the Groupe Mye´lome Autogreffe specifically examined the role of early HDT vs HDT used as salvage therapy at the time of relapse from continued initial therapy. 29 The MAG90 trial randomized 185 patients up to 56 years of age to receive HDT after 3-4 cycles of initial therapy or to continue on conventional therapy with HDT carried out at the time of first relapse or in the event of refractoriness to initial therapy. At a median follow-up of 58 months, estimated median OS was identical in the two groups (64.6 months in the early HDT group and 64 months in the delayed group). However, TWiSTT was significantly better for the early HDT group (27.8 vs 22.3 months). While the Intergroup trial and the MAG91 trials did not directly address the question of timing of HDT, the availability of HDT as a salvage therapy for patients receiving conventional therapy allows us to confirm the equivalence of delayed and early HDT for MM.
Peripheral blood is the source of choice currently for stem cells, given the more rapid engraftment, ease of stem cell collection and less contamination with myeloma cells. [30] [31] [32] There are many options for mobilizing regimens, from single-agent granulocyte colony-stimulating factor (G-CSF), 33 to pegylated G-CSF, 34 to an assortment of chemotherapy plus growth factor regimens. [35] [36] [37] [38] [39] In general, chemotherapy mobilization results in higher CD34 yields. 35, 40, 41 Most of the studies have not specifically noted an effect of age on the stem cell collection. In one study of 984 MM patients, including 106 patients aged X70 years, an inverse correlation was observed between increasing age and CD34 þ yield. 25 The effect of age was incremental with no age threshold showing acceleration in the decline of CD34 þ yield. The authors also found significantly delayed platelet recovery in the elderly patients if o2 Â 10 6 /kg CD34 þ cells were infused, but this effect was eliminated completely with infusion of X4 Â 10 6 /kg CD34 þ cells. In another study, 21 consecutive progenitor cell mobilizations in 15 patients under 60 years (median age 56 years; range 37-59 years) were compared to 33 consecutive mobilizations in 23 patients 460 years (median age 65 years; range 60-73 years) of age. 42 The number of CD34 þ circulating cells before apheresis was significantly lower in the elderly patients. In patients 460 years, 13/33 mobilizations were not successful (39%), compared to 6/21 mobilizations (29%) in the younger population. Desikan et al. 43 analyzed the impact of age on PBSC procurement and engraftment after HDT in 117 MM patients mobilized with G-CSF alone. While there was no effect on the stem cell collection, platelet engraftment was delayed in the older patients. Another study including 225 patients, undergoing stem cell mobilization with high-dose cyclophosphamide and hematopoietic growth factors, found no difference in either the median number of CD34 þ cells collected or time to engraftment between patients over 60 years compared to younger patients. 44 Pre-transplant therapy of newly diagnosed myeloma
The long-term impact of the initial therapy in patients with newly diagnosed myeloma leading to HDT remains undefined and several regimens have been used for the initial treatment of these patients. It is clear that melphalan-containing regimens can impact the ability to collect adequate number of stem cells for a stem cell transplant and care should be taken to avoid repeated cycles of such regimens before stem cell collection. 45 Available data would suggest that the degree of response to the initial therapy does not impact the long-term outcome in patients undergoing stem cell transplant. Several retrospective studies have looked at the role of HDT in patients who fail to achieve a response to initial therapy. We evaluated the outcome of ASCT among 50 patients with primary refractory MM comparing it to 101 patients with chemosensitive disease. 46 There was no difference in the response rates or in the EFS and OS between the groups. Similar results have been observed in other studies as well. 47, 48 The most commonly used initial regimen until recently had been VAD or single-agent dexamethasone. Our own experience has been that single-agent dexamethasone is much better tolerated compared to VAD with only slightly lower response rates and equivalent outcome following ASCT. 49 However, with the introduction of the newer agents, this paradigm has changed. The combination of thalidomide and dexamethasone has been compared to dexamethasone alone in phase III trials in patients with newly diagnosed myeloma. 50 Rajkumar et al. studied 207 patients randomly assigned to thalidomide plus dexamethasone or dexamethasone alone. The response rate with thalidomide plus dexamethasone was significantly higher than with dexamethasone alone (63 vs 41%, respectively). The incidence rates of grade 3 or higher deep-vein thrombosis, rash, bradycardia, neuropathy, and any grade 4-5 toxicity in the first 4 months were significantly higher with thalidomide plus dexamethasone compared with dexamethasone alone (45 vs 21%, respectively). Phase II trials of lenalidomide in combination with dexamethasone have resulted in high response rates in patients with newly diagnosed MM. 51, 52 Bortezomib-based combinations are undergoing phase III trials in the setting of newly diagnosed myeloma. Our current approach is the combination of lenalidomide and dexamethasone, an effective regimen for newly diagnosed myeloma, which is well tolerated by older patients.
Role of second transplant: tandem transplant vs salvage second transplant?
With HDT highlighting the importance of dose intensity in the treatment of patients with MM, the next question was whether further consolidation can be achieved with additional cycles of HDT and stem cell transplant. The studies published so far have primarily looked at patients under 65 years. Investigators at the University of Arkansas initially reported on the use of sequential HDT in their Total Therapy I protocol, where they studied 231 patients with newly diagnosed myeloma treated with a series of induction regimens and two cycles of high-dose therapy. 53 Three randomized trials have directly addressed the question of single vs double upfront transplants. The IFM-94 trial randomized 399 previously untreated patients under the age of 60 years to receive a single or double transplant. Only a slight improvement in the combined CR and VGPR rate was seen with double transplant (50 vs 42%, P ¼ 0.1), but the EFS (20 vs 10%) and the OS (42 vs 21%) at 7 years post transplant doubled with addition of the second HDT. The benefit of second transplant was the most significant among those failing to achieve a VGPR within 3 months after the first transplant (OS of 43% in the double HDT arm vs 11% in the single HDT arm at 7 years). The Bologna 96 clinical trial randomized 228 patients under 60 years with newly diagnosed MM to a single HDT with MEL200 or an additional cycle of HDT within 3-6 months of initial HDT using melphalan 120 mg/m 2 þ busulfan 12 mg/kg for conditioning. 54 Patients received four cycles of VAD for induction therapy followed by collection of PBSCs with high-dose cyclophosphamide and growth factors. At a median follow-up of 54 months, addition of a second HDT prolonged EFS by 12 months and time to progression by 17 months with a projected OS at 6 years of 44% for single transplant and 63% for double transplant (P ¼ 0.3). As with the French study, patients who failed to achieve a CR or nCR after the first HDT obtained the maximum benefit from the second cycle of HDT and had a significantly better outcome. Published experience from the University of Arkansas suggests a survival advantage for patients over 70 years undergoing a tandem approach.
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What is the role of maintenance therapy?
High-dose therapy clearly improves the response rates in patients with newly diagnosed myeloma compared to conventional therapy, but patients invariably relapse. Attempts at maintaining the initial responses through maintenance approaches have been studied. IFN, based on promising initial studies in the setting of conventional chemotherapy, was the first to be studied. In a small randomized clinical trial, 85 patients received either maintenance treatment with IFNa, 3 Â 10 6 units/m 2 subcutaneously three times weekly until relapse or no further treatment following initial HDT. 55 Even though initial results appeared to demonstrate benefit for maintenance therapy in terms of EFS and OS, with longer follow-up the differences were no longer significant, partly a reflection of the small size of the study.
Several ongoing and partially reported clinical trials evaluate the role of thalidomide or lenalidomide as maintenance therapy after HDT. The IFM 99-02 randomized 597 patients with standard risk myeloma (b2-microglobulin (B2M) o3 and no deletion 13), 2 months after tandem HDT, to receive no maintenance, pamidronate or pamidronate plus thalidomide. 56 The overall response rates were significantly higher for the thalidomide arm and this translated into an improved EFS of 52% compared to 36% with no maintenance and 37% with pamidronate alone (Po0.009). The 4-year estimated survival from diagnosis was higher with thalidomide (87%) compared to 77% with no maintenance (Po0.04). Long-term results of these trials should be awaited before adopting this into routine practice. However, this trial only enrolled patients under 65 years of age. Stewart et al. reported on 67 patients who received HDT within 1 year of treatment onset who were initiated on 50 mg of prednisone by mouth on alternate days and thalidomide at a starting dose of either 200 or 400 mg daily within 60-100 days after HDT. 57 The primary end point of this study was tolerability of the regimen. Allowing for dose reduction, 76% of patients assigned to the 200 mg of thalidomide arm and 41% of patients assigned to the 400 mg of thalidomide arm remained on any maintenance therapy 18 months after registration. An ongoing large intergroup study is currently evaluating the role of this dose of thalidomide as a maintenance strategy after single HDT. Other phase II studies have also evaluated the feasibility of thalidomide in this setting. 58 Another large ongoing trial is evaluating lenalidomide as maintenance therapy after single HDT.
Allogeneic SCT
Allogeneic approaches to treatment of myeloma have been associated with high treatment-related toxicity and mortality in this patient population. While some of the high regimen-related toxicities are a function of the advanced disease status of the majority of the patients, identification of high-risk patients likely to benefit from this approach still remains suboptimal. The presence of graft vs myeloma effect is obvious from the significantly higher rate of molecular responses following allogeneic stem cell transplant compared to ASCT which often translate into longer remission duration. 59, 60 Most of the available data comes from single institution experience or from registry data and suffers from selection bias. These studies have attempted to compare the results to similar group of patients undergoing ASCT, but have not been able to demonstrate a survival advantage for the allogeneic approaches. While the introduction of reduced intensity and non-myeloablative transplants has resulted in decreased treatment-related mortality, the survival improvements have not been demonstrated. Use of non-myeloablative approaches has made this option available for the older patients, though there is limited information on the toxicity and efficacy of this approach in these patients. We would recommend consideration of allogeneic approaches in this population in selected situations and only within the context of a clinical trial.
Non-transplant approaches for elderly
Given the median age of the patient population at diagnosis, efforts have been made to examine the role of various non-transplant approaches in patients over 65 years. The combination of MP, usually avoided in the setting of anticipated transplant, has been the cornerstone of therapy for older patients with myeloma. The advent of newer drugs has led to clinical trials attempting to improve on this therapy. Thalidomide when added to MP has been shown to be very effective in randomized phase 2 trials. This combination results in improved PFS and OS compared to MP, albeit at higher toxicity, primarily cardiovascular and infectious. 28, 61 In view of these results, melphalan, prednisone, thalidomide (MPT) is increasingly being accepted as standard therapy for older, non-transplant eligible patients with newly diagnosed myeloma. 62 Ongoing phase I and II trials continue to evaluate the addition of lenalidomide or bortezomib to the MP regimen, and the results so far appear promising.
Conclusions and future directions
HDT and stem cell transplantation is an effective therapy for management of MM. While previous randomized clinical trials have demonstrated a survival advantage for this approach compared to conventional chemotherapy, its role has come under intense debate with the introduction of effective new agents. Even though none of the prospective trials directly evaluated its role in the patients over 65 years, collective experience from different institutions would support the use of HDT in selected older patients. Clearly, these studies have selected patients based on performance status and co-morbidities, but the lack of prospectively defined clinical trials prevent us from providing guidelines for patient selection. The approaches to initial therapy of myeloma, timing of transplant and the stem cell collection process remain the same for older patients as they are for the younger patients. However, the reduction in melphalan dose should be considered for some of these patients based on renal function as well as other co-morbidities. Use of maintenance therapies should await results of ongoing trials before widespread adoption. Future clinical trials evaluating treatment options for myeloma, especially the question of HDT, should specifically include this patient group. Such studies in addition to antitumor efficacy end points also need to incorporate quality of life assessments, since treatments are more likely to have a deleterious impact on the older patients. More importantly, clinical trials evaluating non-HDT approaches should specifically evaluate the impact on older patients.
